 |
53 Diseases |  |
17 Trials |
|
17 Trials |  |
785 News |  |
| «12...3456789101112131415» |
- || Adempas (riociguat) / Bayer, Merck (MSD)
Enrollment closed: CAPTURE: A Study to Understand the Treatment Patterns in Patients With Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension During a Switch of Treatment to Adempas in Real-life Clinical Practice (clinicaltrials.gov) - Jun 9, 2016
P=N/A, N=80, Active, not recruiting, Sponsor: Bayer
Recruiting --> Active, not recruiting
- | Adempas (riociguat) / Bayer, Merck (MSD)
Trial termination, Trial primary completion date: RISE-IIP: Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP) (clinicaltrials.gov) - May 20, 2016
P2, N=147, Terminated, Sponsor: Bayer
Recruiting --> Terminated | Trial primary completion date: Oct 2016 --> May 2016; Study terminated per recommendation of iDMC. On iDMC request, protocol amended to include 4-month safety follow-up for patients after withdrawal of riociguat.
- || Adempas (riociguat) / Bayer, Merck (MSD)
Trial primary completion date: RISE-IIP: Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP) (clinicaltrials.gov) - May 5, 2016
P2, N=135, Recruiting, Sponsor: Bayer
On iDMC request, protocol amended to include 4-month safety follow-up for patients after withdrawal of riociguat. Trial primary completion date: Jan 2017 --> Oct 2016
- |||| Adempas (riociguat) / Bayer, Merck (MSD)
Trial primary completion date: RESPITE: Riociguat Clinical Effects Studied in Patients With Insufficient Treatment Response to Phosphodiesterase-5 Inhibitor (clinicaltrials.gov) - May 5, 2016
P3, N=61, Active, not recruiting, Sponsor: Bayer
Trial primary completion date: Jan 2017 --> Oct 2016 Trial primary completion date: Jun 2016 --> Dec 2017
- || Adempas (riociguat) / Bayer, Merck (MSD)
Trial primary completion date: RISE-SSc: Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis (clinicaltrials.gov) - May 4, 2016
P2, N=130, Recruiting, Sponsor: Bayer
Trial primary completion date: Jun 2016 --> Dec 2017 Trial primary completion date: Jul 2017 --> Jan 2018
- Adempas (riociguat) / Bayer, Merck (MSD)
Enrollment closed, Enrollment change, Trial primary completion date: Pilot Study to Evaluate Right Ventricular Function With Riociguat in CTEPH (clinicaltrials.gov) - May 3, 2016
P2, N=6, Active, not recruiting, Sponsor: Ottawa Heart Institute Research Corporation
Trial primary completion date: Jul 2017 --> Jan 2018 Recruiting --> Active, not recruiting | N=10 --> 6 | Trial primary completion date: Mar 2016 --> Jun 2016
- | Adempas (riociguat) / Bayer, Merck (MSD)
New P4 trial: RIALTO: A Long-term Extension Study of Riociguat in Patients With Symptomatic Pulmonary Arterial Hypertension. (clinicaltrials.gov) - May 3, 2016
P4, N=14, Not yet recruiting, Sponsor: Bayer
- Adempas (riociguat) / Bayer, Merck (MSD)
Trial primary completion date: Interaction With HIV Antiretroviral Agents (clinicaltrials.gov) - Apr 27, 2016
P1, N=40, Recruiting, Sponsor: Bayer
Recruiting --> Active, not recruiting | N=10 --> 6 | Trial primary completion date: Mar 2016 --> Jun 2016 Trial primary completion date: Dec 2016 --> Apr 2017
- | Adempas (riociguat) / Bayer, Merck (MSD)
New P2 trial: Pharmacodynamic Effects of Riociguat in Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction (clinicaltrials.gov) - Apr 20, 2016
P2, N=114, Recruiting, Sponsor: Medical University of Vienna
- Adempas (riociguat) / Bayer, Merck (MSD)
Trial primary completion date: Early Signs of Efficacy Study With Riociguat in Adult Homozygous Delta F508 Cystic Fibrosis Patients (clinicaltrials.gov) - Mar 25, 2016
P2, N=36, Recruiting, Sponsor: Bayer
Trial primary completion date: Dec 2016 --> Apr 2017 Trial primary completion date: Feb 2017 --> Sep 2017
- Adempas (riociguat) / Bayer, Merck (MSD)
Enrollment open, Trial primary completion date: Interaction With HIV Antiretroviral Agents (clinicaltrials.gov) - Mar 22, 2016
P1, N=40, Recruiting, Sponsor: Bayer
Trial primary completion date: Feb 2017 --> Sep 2017 Not yet recruiting --> Recruiting | Trial primary completion date: Jan 2018 --> Dec 2016
- Adempas (riociguat) / Bayer, Merck (MSD)
Enrollment change: Relative Bioavailability Study (clinicaltrials.gov) - Feb 18, 2016
P1, N=48, Completed, Sponsor: Bayer
Not yet recruiting --> Recruiting | Trial primary completion date: Jan 2018 --> Dec 2016 N=25 --> 48
- ||| Adempas (riociguat) / Bayer, Merck (MSD)
Enrollment closed, Enrollment change: Measuring Outcomes In Patients With Pulmonary Arterial Hypertension Not on Active Treatment (MOTION) (clinicaltrials.gov) - Feb 17, 2016
P4, N=75, Active, not recruiting, Sponsor: Bayer
N=25 --> 48 Recruiting --> Active, not recruiting | N=100 --> 75
- || Adempas (riociguat) / Bayer, Merck (MSD)
Trial primary completion date: CAPTURE: A Study to Understand the Treatment Patterns in Patients With Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension During a Switch of Treatment to Adempas in Real-life Clinical Practice (clinicaltrials.gov) - Feb 17, 2016
P=N/A, N=80, Recruiting, Sponsor: Bayer
Recruiting --> Active, not recruiting | N=100 --> 75 Trial primary completion date: Sep 2016 --> May 2016
- Adempas (riociguat) / Bayer, Merck (MSD)
Trial completion, Enrollment change: Efficacy Study of Riociguat and Its Effects on Exercise Performance and Pulmonary Artery Pressure at High Altitude (clinicaltrials.gov) - Jan 25, 2016
P4, N=28, Completed, Sponsor: Richard Moon
Trial primary completion date: Sep 2016 --> May 2016 Active, not recruiting --> Completed | N=20 --> 28
- Adempas (riociguat) / Bayer, Merck (MSD)
Trial primary completion date: Interaction With HIV Antiretroviral Agents (clinicaltrials.gov) - Jan 17, 2016
P1, N=40, Not yet recruiting, Sponsor: Bayer
Active, not recruiting --> Completed | N=20 --> 28 Trial primary completion date: Oct 2016 --> Jan 2018
- Adempas (riociguat) / Bayer, Merck (MSD)
Trial primary completion date: Pilot Study to Evaluate Right Ventricular Function With Riociguat in CTEPH (clinicaltrials.gov) - Jan 17, 2016
P2, N=10, Recruiting, Sponsor: Ottawa Heart Institute Research Corporation
Trial primary completion date: Oct 2016 --> Jan 2018 Trial primary completion date: Nov 2015 --> Mar 2016
- || Adempas (riociguat) / Bayer, Merck (MSD)
Trial primary completion date: JPMS-CTEPH: Prospective, Non-interventional, Multi-center Post-authorization Safety Study of Riociguat for Chronic Thromboembolic Pulmonary Hypertension (CTEPH ) (clinicaltrials.gov) - Dec 21, 2015
P=N/A, N=420, Recruiting, Sponsor: Bayer
Trial primary completion date: Nov 2015 --> Mar 2016 Trial primary completion date: Mar 2023 --> Sep 2022
- || Adempas (riociguat) / Bayer, Merck (MSD)
Trial primary completion date: CAPTURE: A Study to Understand the Treatment Patterns in Patients With Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension During a Switch of Treatment to Adempas in Real-life Clinical Practice (clinicaltrials.gov) - Dec 21, 2015
P=N/A, N=80, Recruiting, Sponsor: Bayer
Trial primary completion date: Mar 2023 --> Sep 2022 Trial primary completion date: Jan 2016 --> Sep 2016
- ||| Adempas (riociguat) / Bayer, Merck (MSD)
New trial: RACE: Riociguat Versus Balloon Pulmonary Angioplasty in Non-operable Chronic thromboEmbolic Pulmonary Hypertension (clinicaltrials.gov) - Dec 17, 2015
P=N/A, N=124, Not yet recruiting, Sponsor: Assistance Publique - H
- | Adempas (riociguat) / Bayer, Merck (MSD)
New P2 trial: A Multi-Center Study of Riociguat in Patients With Sickle Cell Diseases (clinicaltrials.gov) - Dec 17, 2015
P2, N=100, Not yet recruiting, Sponsor: Gregory J. Kato, MD
- | Adempas (riociguat) / Bayer, Merck (MSD)
New P4 trial: RioSAPH: Riociguat for Sarcoidosis Associated Pulmonary Hypertension (clinicaltrials.gov) - Dec 10, 2015
P4, N=60, Recruiting, Sponsor: University of Cincinnati
- Adempas (riociguat) / Bayer, Merck (MSD)
Enrollment closed, Trial primary completion date: Efficacy Study of Riociguat and Its Effects on Exercise Performance and Pulmonary Artery Pressure at High Altitude (clinicaltrials.gov) - Dec 10, 2015
P4, N=20, Active, not recruiting, Sponsor: Richard Moon
Trial primary completion date: Jan 2016 --> Sep 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2015 --> Dec 2015
- | Adempas (riociguat) / Bayer, Merck (MSD)
Enrollment open: PATENT-CHILD: Riociguat in Children With Pulmonary Arterial Hypertension (PAH) (clinicaltrials.gov) - Nov 30, 2015
P3, N=20, Recruiting, Sponsor: Bayer
Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2015 --> Dec 2015 Not yet recruiting --> Recruiting
- ||||| Adempas (riociguat) / Bayer, Merck (MSD)
Enrollment closed: RESPITE: Riociguat Clinical Effects Studied in Patients With Insufficient Treatment Response to Phosphodiesterase-5 Inhibitor (clinicaltrials.gov) - Nov 11, 2015
P3, N=60, Active, not recruiting, Sponsor: Bayer
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- |||| Adempas (riociguat) / Bayer, Merck (MSD)
Trial primary completion date: PATENT-2: BAY63-2521:Long-term Extension Study in Patients With Pulmonary Arterial Hypertension (clinicaltrials.gov) - Oct 22, 2015
P3, N=396, Active, not recruiting, Sponsor: Bayer
Recruiting --> Active, not recruiting Trial primary completion date: May 2016 --> Mar 2019
- ||| Adempas (riociguat) / Bayer, Merck (MSD)
New P3 trial: PATENT-CHILD: Riociguat in Children With Pulmonary Arterial Hypertension (PAH) (clinicaltrials.gov) - Sep 29, 2015
P3, N=20, Not yet recruiting, Sponsor: Bayer
- | Adempas (riociguat) / Bayer, Merck (MSD)
New P1 trial: Interaction With HIV Antiretroviral Agents (clinicaltrials.gov) - Sep 22, 2015
P1, N=40, Not yet recruiting, Sponsor: Bayer
- ||| Adempas (riociguat) / Bayer, Merck (MSD)
New trial: CAPTURE: A Study to Understand the Treatment Patterns in Patients With Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension During a Switch of Treatment to Adempas in Real-life Clinical Practice (clinicaltrials.gov) - Sep 10, 2015
P=N/A, N=80, Not yet recruiting, Sponsor: Bayer
- Adempas (riociguat) / Bayer, Merck (MSD)
Trial primary completion date: Early Signs of Efficacy Study With Riociguat in Adult Homozygous Delta F508 Cystic Fibrosis Patients (clinicaltrials.gov) - Aug 21, 2015
P2, N=36, Recruiting, Sponsor: Bayer
Trial primary completion date: May 2016 --> Mar 2019 Trial primary completion date: May 2016 --> Feb 2017
- Adempas (riociguat) / Bayer, Merck (MSD)
Trial primary completion date: Pilot Study to Evaluate Right Ventricular Function With Riociguat in CTEPH (clinicaltrials.gov) - Aug 21, 2015
P2, N=10, Recruiting, Sponsor: Ottawa Heart Institute Research Corporation
Trial primary completion date: May 2016 --> Feb 2017 Trial primary completion date: May 2015 --> Nov 2015
- ||| Adempas (riociguat) / Bayer, Merck (MSD)
Enrollment change: Measuring Outcomes In Patients With Pulmonary Arterial Hypertension Not on Active Treatment (MOTION) (clinicaltrials.gov) - Aug 21, 2015
P4, N=100, Recruiting, Sponsor: Bayer
Trial primary completion date: May 2015 --> Nov 2015 N=61 --> 100
- ||| Adempas (riociguat) / Bayer, Merck (MSD)
Enrollment open: JPMS-PAH: Prospective, Non-interventional, Multi-center, Post-authorization Safety Study of Riociguat for Pulmonary Arterial Hypertension (PAH) (clinicaltrials.gov) - Jul 17, 2015
P=N/A, N=600, Recruiting, Sponsor: Bayer
N=61 --> 100 Not yet recruiting --> Recruiting
- Adempas (riociguat) / Bayer, Merck (MSD)
Trial primary completion date: Impact of Multiple Doses of BAY63-2521 on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Patients With Interstitial Lung Disease (ILD) Associated Pulmonary Hypertension (PH) (clinicaltrials.gov) - Jun 11, 2015
P2, N=22, Active, not recruiting, Sponsor: Bayer
Not yet recruiting --> Recruiting Trial primary completion date: Oct 2015 --> Oct 2018
- ||| Adempas (riociguat) / Bayer, Merck (MSD)
New trial: JPMS-PAH: Prospective, Non-interventional, Multi-center, Post-authorization Safety Study of Riociguat for Pulmonary Arterial Hypertension (PAH) (clinicaltrials.gov) - Apr 29, 2015
P=N/A, N=600, Not yet recruiting, Sponsor: Bayer
- ||| Adempas (riociguat) / Bayer, Merck (MSD)
Enrollment change: Measuring Outcomes In Patients With Pulmonary Arterial Hypertension Not on Active Treatment (MOTION) (clinicaltrials.gov) - Apr 28, 2015
P4, N=61, Recruiting, Sponsor: Bayer
Trial primary completion date: Oct 2015 --> Oct 2018 N=100 --> 61
- | Adempas (riociguat) / Bayer, Merck (MSD)
Trial completion, Enrollment change: Microgynon Riociguat Drug Interaction Study in Healthy Postmenopausal Women (clinicaltrials.gov) - Mar 26, 2015
P1, N=31, Completed, Sponsor: Bayer
N=100 --> 61 Active, not recruiting --> Completed | N=12 --> 31
- Adempas (riociguat) / Bayer, Merck (MSD)
Enrollment closed, Enrollment change: Microgynon Riociguat Drug Interaction Study in Healthy Postmenopausal Women (clinicaltrials.gov) - Mar 10, 2015
P1, N=12, Active, not recruiting, Sponsor: Bayer
Active, not recruiting --> Completed | N=12 --> 31 Recruiting --> Active, not recruiting | N=24 --> 12
- |||| Adempas (riociguat) / Bayer, Merck (MSD)
Trial primary completion date: CHEST-2: BAY63-2521 - Long-term Extension Study in Patients With Chronic Thromboembolic Pulmonary Hypertension (clinicaltrials.gov) - Feb 24, 2015
P3, N=237, Active, not recruiting, Sponsor: Bayer
Recruiting --> Active, not recruiting | N=24 --> 12 Trial primary completion date: May 2016 --> Mar 2019
- |||| Adempas (riociguat) / Bayer, Merck (MSD)
Enrollment open: RISE-SSc: Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis (clinicaltrials.gov) - Feb 19, 2015
P2, N=130, Recruiting, Sponsor: Bayer
Trial primary completion date: May 2016 --> Mar 2019 Not yet recruiting --> Recruiting
- Adempas (riociguat) / Bayer, Merck (MSD)
Trial primary completion date: Early Signs of Efficacy Study With Riociguat in Adult Homozygous Delta F508 Cystic Fibrosis Patients (clinicaltrials.gov) - Feb 5, 2015
P2, N=36, Recruiting, Sponsor: Bayer
Not yet recruiting --> Recruiting Trial primary completion date: Aug 2015 --> Mar 2016
- || Adempas (riociguat) / Bayer, Merck (MSD)
Trial primary completion date: RISE-IIP: Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP) (clinicaltrials.gov) - Jan 30, 2015
P2, N=120, Recruiting, Sponsor: Bayer
Trial primary completion date: Aug 2015 --> Mar 2016 Trial primary completion date: Mar 2016 --> Jan 2017
- Adempas (riociguat) / Bayer, Merck (MSD)
Enrollment open, Trial primary completion date: Efficacy Study of Riociguat and Its Effects on Exercise Performance and Pulmonary Artery Pressure at High Altitude (clinicaltrials.gov) - Dec 10, 2014
P4, N=20, Recruiting, Sponsor: Richard Moon
Trial primary completion date: Mar 2016 --> Jan 2017 Not yet recruiting --> Recruiting | Trial primary completion date: Sep 2014 --> Sep 2015
- Adempas (riociguat) / Bayer, Merck (MSD)
Enrollment closed: Relative Bioavailability Study (clinicaltrials.gov) - Dec 9, 2014
P1, N=25, Active, not recruiting, Sponsor: Bayer
Not yet recruiting --> Recruiting | Trial primary completion date: Sep 2014 --> Sep 2015 Completed --> Active, not recruiting
- ||||| Adempas (riociguat) / Bayer, Merck (MSD)
New P2 trial: RISE-SSc: Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis (clinicaltrials.gov) - Nov 5, 2014
P2, N=130, Not yet recruiting, Sponsor: Bayer
- | Adempas (riociguat) / Bayer, Merck (MSD)
Trial completion: Relative Bioavailability Study (clinicaltrials.gov) - Oct 30, 2014
P1, N=25, Completed, Sponsor: Bayer
Completed --> Active, not recruiting Active, not recruiting --> Completed
- | Adempas (riociguat) / Bayer, Merck (MSD)
Enrollment open: Early Signs of Efficacy Study With Riociguat in Adult Homozygous Delta F508 Cystic Fibrosis Patients (clinicaltrials.gov) - Oct 17, 2014
P2, N=36, Recruiting, Sponsor: Bayer
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- |||| Adempas (riociguat) / Bayer, Merck (MSD)
Enrollment open: Measuring Outcomes In Patients With Pulmonary Arterial Hypertension Not on Active Treatment (MOTION) (clinicaltrials.gov) - Oct 15, 2014
P4, N=100, Recruiting, Sponsor: Bayer
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Adempas (riociguat) / Bayer, Merck (MSD)
Enrollment closed: Relative Bioavailability Study (clinicaltrials.gov) - Sep 16, 2014
P1, N=25, Active, not recruiting, Sponsor: Bayer
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- ||| Adempas (riociguat) / Bayer, Merck (MSD)
Enrollment open: JPMS-CTEPH: Prospective, Non-interventional, Multi-center Post-authorization Safety Study of Riociguat for Chronic Thromboembolic Pulmonary Hypertension (CTEPH ) (clinicaltrials.gov) - Sep 8, 2014
P=N/A, N=420, Recruiting, Sponsor: Bayer
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting